Outcome of Board Meeting held on 01st August, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Link Pharma Chem's board approved the unaudited financial results for Q1 FY26 (quarter ended 30th June 2025), along with a limited review report from auditor CNK & Associates LLP. Revenue from operations stood at Rs 781.48 lakhs, down from Rs 884.63 lakhs in the same quarter last year. However, the company swung to a profit of Rs 40.19 lakhs compared to a profit of Rs 29.64 lakhs in Q1 FY25, and recovered from a loss of Rs 35.02 lakhs in Q4 FY25. The board also approved the re-appointment of Mrs. Rachna Manav Ghai as a Woman Independent Director for a second term of five years starting 14th September 2025, subject to shareholder approval.
This is a routine quarterly results filing with no major governance red flags. The year-on-year profit growth despite lower revenue signals improved cost control, particularly in raw materials, which may be viewed positively by shareholders.